YMAB Share Price Performance
US$8.61
-0.17 (-1.94%)
0.1% overvalued intrinsic discount
US$8.60
Fair Value
Price US$8.61
AnalystConsensusTarget US$8.60
Fair ValueUS$8.60
Share Pricen/a
Y-mAbs Therapeutics, Inc. Stock Price
- 1 Narratives written by author
- 0 Comments on narratives written by author
- 3 Fair Values set on narratives written by author
YMAB Community Narratives
AN
Fair Value US$8.6 0.1% overvalued intrinsic discount
Pipeline Developments And Radiopharmaceutical Advances Will Extend Global Reach
0users have liked this narrative
0users have commented on this narrative
3users have followed this narrative
Pipeline Developments And Radiopharmaceutical Advances Will Extend Global Reach
Key Takeaways Stronger market adoption of DANYELZA and international expansion are expected to drive recurring revenue and broaden the patient base. Advancements in antibody engineering and rare oncology pipeline will support new product launches and profitable long-term growth.Read more
28
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
3users have followed this narrative
AN
US$8.6
0.1% overvalued intrinsic discount
AnalystConsensusTarget's Fair Value
Revenue
12.13% p.a.
Profit Margin
16.06%
Future PE
25.45x
Price in 2028
US$10.37
Trending Discussion
Recently Updated Narratives
AN
Pipeline Developments And Radiopharmaceutical Advances Will Extend Global Reach
Fair Value: US$8.6 0.1% overvalued intrinsic discount
3 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
Y-mAbs Therapeutics, Inc. Key Details
About YMAB
- Founded
- 2015
- Employees
- 104
- CEO
- WebsiteView website
Y-mAbs Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of radioimmunotherapy and antibody based therapeutic products for the treatment of cancer. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow. The company also develops DANYELZA for the treatment of patients with second-line relapsed osteosarcoma and is in Phase II clinical study; GD2-SADA, which is in Phase I clinical trial for the treatment of GD2 positive solid tumors; and Omburtamab, an antibody for the treatment of central nervous system/leptomeningeal metastases from neuroblastoma. In addition, it engages in the development of CD38-SADA and GD2-GD3 Vaccine; and offers self-assembly disassembly pretargeted radioimmuno therapy (SADA PRIT) technology platform to deliver the radioactive payload to the tumor. The company has a license agreement with Memorial Sloan Kettering Cancer Center and Massachusetts Institute of Technology to develop and commercialize licensed products. It operates in the United States, Western Europe, Eastern Asia, Latin America, Western Asia, and internationally. Y-mAbs Therapeutics, Inc. was incorporated in 2015 and is headquartered in Princeton, New Jersey.
